Centiva Capital LP Invests $636,000 in STERIS plc (NYSE:STE)

Centiva Capital LP acquired a new stake in STERIS plc (NYSE:STE - Free Report) in the 4th quarter, according to its most recent filing with the SEC. The fund acquired 3,096 shares of the medical equipment provider's stock, valued at approximately $636,000.

Several other institutional investors and hedge funds also recently made changes to their positions in STE. Avalon Trust Co acquired a new stake in STERIS in the 4th quarter valued at $30,000. Human Investing LLC acquired a new stake in shares of STERIS in the fourth quarter valued at about $31,000. Anfield Capital Management LLC raised its holdings in STERIS by 100.0% during the fourth quarter. Anfield Capital Management LLC now owns 182 shares of the medical equipment provider's stock worth $37,000 after acquiring an additional 91 shares in the last quarter. Manchester Capital Management LLC boosted its position in STERIS by 182.7% during the fourth quarter. Manchester Capital Management LLC now owns 212 shares of the medical equipment provider's stock valued at $44,000 after purchasing an additional 137 shares during the last quarter. Finally, Brown Brothers Harriman & Co. boosted its position in STERIS by 66.7% during the fourth quarter. Brown Brothers Harriman & Co. now owns 220 shares of the medical equipment provider's stock valued at $45,000 after purchasing an additional 88 shares during the last quarter. Institutional investors and hedge funds own 94.69% of the company's stock.

Analyst Ratings Changes

Several analysts have issued reports on STE shares. JMP Securities reaffirmed a "market outperform" rating and set a $265.00 price target on shares of STERIS in a research report on Thursday, April 10th. Piper Sandler raised their target price on shares of STERIS from $260.00 to $265.00 and gave the company an "overweight" rating in a research note on Monday, February 3rd. Stephens raised STERIS to a "strong-buy" rating in a research report on Thursday, May 1st. Finally, Needham & Company LLC reaffirmed a "hold" rating on shares of STERIS in a research report on Monday, April 7th. One equities research analyst has rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Buy" and a consensus price target of $258.75.

STERIS Stock Performance

Shares of NYSE:STE traded up $6.46 during trading on Monday, reaching $232.89. 706,030 shares of the stock were exchanged, compared to its average volume of 537,212. The firm has a market cap of $22.88 billion, a PE ratio of 49.45 and a beta of 0.96. The company has a current ratio of 2.13, a quick ratio of 1.40 and a debt-to-equity ratio of 0.32. STERIS plc has a 12 month low of $200.98 and a 12 month high of $248.24. The stock has a 50-day moving average price of $223.40 and a 200-day moving average price of $218.80.

STERIS Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, June 26th. Shareholders of record on Tuesday, June 10th will be issued a $0.57 dividend. This represents a $2.28 dividend on an annualized basis and a yield of 0.98%. The ex-dividend date of this dividend is Tuesday, June 10th. STERIS's dividend payout ratio is 48.41%.

STERIS Company Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.